Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Operating expenses:
Research and development expenses	$ 6,803,900	$ 6,448,528	$ 18,035,762	$ 20,297,066
General and administrative expenses	3,374,794	4,071,158	10,924,863	12,341,207
Total operating expenses	10,178,694	10,519,686	28,960,625	32,638,273
Loss from operations	(10,178,694)	(10,519,686)	(28,960,625)	(32,638,273)
Interest income (expenses), net
Interest income	666,770	739,404	2,010,874	2,219,399
Interest expense	(1,214,734)	(1,068,887)	(3,577,450)	(3,031,129)
Interest income (expenses), net	(547,964)	(329,483)	(1,566,576)	(811,730)
Loss before income taxes	(10,726,658)	(10,849,169)	(30,527,201)	(33,450,003)
Benefit for income taxes	0	0	869,169	1,406,021
Net loss	(10,726,658)	(10,849,169)	(29,658,032)	(32,043,982)
Comprehensive loss	$ (10,726,658)	$ (10,849,169)	$ (29,658,032)	$ (32,043,982)
Per share information:
Net loss per share, basic (in dollars per share)	$ (0.29)	$ (0.35)	$ (0.82)	$ (1.04)
Net loss per share, diluted (in dollars per share)	$ (0.29)	$ (0.35)	$ (0.82)	$ (1.04)
Weighted average common shares outstanding, basic (in shares)	36,806,592	30,910,520	36,107,900	30,715,458
Weighted average common shares outstanding, diluted (in shares)	36,806,592	30,910,520	36,107,900	30,715,458